%0 Journal Article
%A Le Cornet, Charlotte
%A Jung, Audrey Ying-Chee
%A Behrens, Sabine
%A Middha, Pooja
%A Truong, Thérèse
%A Jernström, Helena
%A Bolla, Manjeet K
%A Wang, Qin
%A Southey, Melissa C
%A Beane Freeman, Laura E
%A Koutros, Stella
%A Stone, Jennifer
%A Rennert, Gad
%A Shulman, Katerina
%A Aronson, Kristan J
%A Murphy, Rachel A
%A Guénel, Pascal
%A Patel, Alpa V
%A Bodelon, Clara
%A Teras, Lauren R
%A Shahi, Shamim
%A Lacey, James V
%A Dossus, Laure
%A Kaaks, Rudolf
%A Holleczek, Bernd
%A Brenner, Hermann
%A Brauch, Hiltrud
%A Hoppe, Reiner
%A Czene, Kamila
%A Hall, Per Frans Leonard
%A Mannermaa, Arto
%A Wu, Anna H
%A Obi, Nadia
%A Michailidou, Kyriaki
%A Panayiotidis, Mihalis I
%A McLean, Catriona
%A Haiman, Christopher A
%A Augustinsson, Annelie
%A Zheng, Wei
%A Shu, Xiao-Ou
%A Perou, Charles M
%A Troester, Melissa A
%A Van Alsten, Sarah
%A Eliassen, A Heather
%A Abubakar, Mustapha
%A Kraft, Peter
%A Ahearn, Thomas U
%A Evans, D Gareth
%A Wolk, Alicja
%A Milne, Roger L
%A Easton, Douglas F
%A Pharoah, Paul D P
%A Schmidt, Marjanka K
%A García-Closas, Montserrat
%A Vachon, Celine M
%A Turzanski-Fortner, Renée
%A Chang-Claude, Jenny
%T Exogenous Hormones, Tumor Intrinsic Subtypes, and Breast Cancer.
%J JAMA network open
%V 8
%N 7
%@ 2574-3805
%C Chicago, Ill.
%I American Medical Association
%M DKFZ-2025-01356
%P e2519236
%D 2025
%Z #EA:C020#LA:C020#
%X Etiologic heterogeneity in breast carcinogenesis needs to be well characterized for targeted prevention. Associations between menopausal hormonal therapy (MHT) and oral contraceptive (OC) use and breast cancer intrinsic-like subtypes are not well understood.To examine whether exogenous hormone use is differentially associated with breast cancer subtypes and to evaluate heterogeneity by intrinsic-like subtypes.This study pooled data from 31 nested and population-based case-control studies involved in the Breast Cancer Association Consortium. The study population included individuals with breast cancer and control participants from 13 case-control studies nested in prospective cohorts (recruited between 1982 and 2011) and 18 population-based case-control studies (recruited between 1990 and 2013). Data analysis was performed in June 2024.MHT use (estrogen-progestin therapy [EPT] or estrogen-only therapy [ET]) in postmenopausal women and OC use in premenopausal women (never, past use, or current use).Breast cancer intrinsic-like subtypes (luminal A-like, luminal B-like, luminal B-ERBB2 [formerly HER2 or HER2/neu]-like, ERBB2 enriched-like, or triple-negative) were determined by immunohistochemistry of tumor sections. Polytomous logistic regression was performed to estimate the association between exogenous hormones and risk of breast cancer by intrinsic-like subtypes. Analyses by subtypes were stratified by body mass index (BMI [calculated as weight in kilograms divided by height in meters squared]; healthy weight, 18.5-<25; overweight, 25-<30; or obesity, ≥30).This study included 42 269 individuals with breast cancer (11 901 [28.2
%K Humans
%K Female
%K Breast Neoplasms: epidemiology
%K Breast Neoplasms: classification
%K Breast Neoplasms: chemically induced
%K Breast Neoplasms: pathology
%K Middle Aged
%K Case-Control Studies
%K Postmenopause
%K Adult
%K Prospective Studies
%K Aged
%K Contraceptives, Oral: adverse effects
%K Premenopause
%K Estrogen Replacement Therapy: adverse effects
%K Estrogen Replacement Therapy: statistics & numerical data
%K Contraceptives, Oral (NLM Chemicals)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:40622713
%2 pmc:PMC12235495
%R 10.1001/jamanetworkopen.2025.19236
%U https://inrepo02.dkfz.de/record/302816